140 related articles for article (PubMed ID: 37494004)
1. Oral enzyme therapy for maple syrup urine disease (MSUD) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates.
Skvorak K; Liu J; Kruse N; Mehmood R; Das S; Jenne S; Chng C; Lao UL; Duan D; Asfaha J; Du F; Teadt L; Sero A; Ching C; Riggins J; Pope L; Yan P; Mashiana H; Ismaili MHA; McCluskie K; Huisman G; Silverman AP
J Inherit Metab Dis; 2023 Nov; 46(6):1089-1103. PubMed ID: 37494004
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of maple syrup urine disease: Focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain α-keto acids.
Amaral AU; Wajner M
Neurochem Int; 2022 Jul; 157():105360. PubMed ID: 35577033
[TBL] [Abstract][Full Text] [Related]
3. Maple syrup urine disease decompensation misdiagnosed as a psychotic event.
Higashimoto T; Whitehead MT; MacLeod E; Starin D; Regier DS
Mol Genet Metab Rep; 2022 Sep; 32():100886. PubMed ID: 35756860
[TBL] [Abstract][Full Text] [Related]
4. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes.
Strauss KA; Carson VJ; Soltys K; Young ME; Bowser LE; Puffenberger EG; Brigatti KW; Williams KB; Robinson DL; Hendrickson C; Beiler K; Taylor CM; Haas-Givler B; Chopko S; Hailey J; Muelly ER; Shellmer DA; Radcliff Z; Rodrigues A; Loeven K; Heaps AD; Mazariegos GV; Morton DH
Mol Genet Metab; 2020 Mar; 129(3):193-206. PubMed ID: 31980395
[TBL] [Abstract][Full Text] [Related]
5. Acute illness in maple syrup urine disease: dynamics of protein metabolism and implications for management.
Thompson GN; Francis DE; Halliday D
J Pediatr; 1991 Jul; 119(1 Pt 1):35-41. PubMed ID: 2066856
[TBL] [Abstract][Full Text] [Related]
6. Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity.
Korein J; Sansaricq C; Kalmijn M; Honig J; Lange B
Int J Neurosci; 1994 Nov; 79(1-2):21-45. PubMed ID: 7744549
[TBL] [Abstract][Full Text] [Related]
7. Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study.
Alili JM; Berleur MP; Husson MC; Mention K; Schiff M; Arnoux JB; Brassier A; Guemman AS; Grisel C; Dubois S; Abi-Wardé MT; Broissand C; Servais A; Dao M; de Lonlay P
Orphanet J Rare Dis; 2022 May; 17(1):202. PubMed ID: 35578286
[TBL] [Abstract][Full Text] [Related]
8. Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation.
Deon M; Guerreiro G; Girardi J; Ribas G; Vargas CR
Int J Dev Neurosci; 2023 Oct; 83(6):489-504. PubMed ID: 37340513
[TBL] [Abstract][Full Text] [Related]
9. Production and characterization of murine models of classic and intermediate maple syrup urine disease.
Homanics GE; Skvorak K; Ferguson C; Watkins S; Paul HS
BMC Med Genet; 2006 Mar; 7():33. PubMed ID: 16579849
[TBL] [Abstract][Full Text] [Related]
10. Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model.
Greig JA; Jennis M; Dandekar A; Chorazeczewski JK; Smith MK; Ashley SN; Yan H; Wilson JM
Mol Genet Metab; 2021; 134(1-2):139-146. PubMed ID: 34454844
[TBL] [Abstract][Full Text] [Related]
11. Successful pregnancy in maple syrup urine disease: a case report and review of the literature.
Grünert SC; Rosenbaum-Fabian S; Schumann A; Schwab KO; Mingirulli N; Spiekerkoetter U
Nutr J; 2018 May; 17(1):51. PubMed ID: 29753318
[TBL] [Abstract][Full Text] [Related]
12. Markers associated with inborn errors of metabolism of branched-chain amino acids and their relevance to upper levels of intake in healthy people: an implication from clinical and molecular investigations on maple syrup urine disease.
Mitsubuchi H; Owada M; Endo F
J Nutr; 2005 Jun; 135(6 Suppl):1565S-70S. PubMed ID: 15930470
[TBL] [Abstract][Full Text] [Related]
13. Clues and challenges in the diagnosis of intermittent maple syrup urine disease.
Pode-Shakked N; Korman SH; Pode-Shakked B; Landau Y; Kneller K; Abraham S; Shaag A; Ulanovsky I; Daas S; Saraf-Levy T; Reznik-Wolf H; Vivante A; Pras E; Almashanu S; Anikster Y
Eur J Med Genet; 2020 Jun; 63(6):103901. PubMed ID: 32151765
[TBL] [Abstract][Full Text] [Related]
14. Treatment of maple syrup urine disease with high flow hemodialysis in a neonate.
Aygün F; Kıykım E; Aktuğlu-Zeybek Ç; Zubarioğlu T; Cam H
Turk J Pediatr; 2019; 61(1):107-110. PubMed ID: 31559730
[TBL] [Abstract][Full Text] [Related]
15. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.
Zinnanti WJ; Lazovic J; Griffin K; Skvorak KJ; Paul HS; Homanics GE; Bewley MC; Cheng KC; Lanoue KF; Flanagan JM
Brain; 2009 Apr; 132(Pt 4):903-18. PubMed ID: 19293241
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of branched-chain amino acids in maple syrup urine disease.
Schadewaldt P; Wendel U
Eur J Pediatr; 1997 Aug; 156 Suppl 1():S62-6. PubMed ID: 9266218
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress in plasma from maple syrup urine disease patients during treatment.
Barschak AG; Sitta A; Deon M; Barden AT; Dutra-Filho CS; Wajner M; Vargas CR
Metab Brain Dis; 2008 Mar; 23(1):71-80. PubMed ID: 18026828
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Branched-Chain Amino Acids in Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Piri-Moghadam H; Miller A; Pronger D; Vicente F; Charrow J; Haymond S; Lin DC
Methods Mol Biol; 2022; 2546():65-81. PubMed ID: 36127579
[TBL] [Abstract][Full Text] [Related]
19. Melatonin improves behavioral parameters and oxidative stress in zebrafish submitted to a leucine-induced MSUD protocol.
Duarte MB; Medeiros BZ; da Silva Lemos I; da Silva GL; Alano CG; Dondossola ER; Torres CA; Effting PS; Rico EP; Streck EL
Metab Brain Dis; 2023 Aug; 38(6):2105-2114. PubMed ID: 37099078
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
